Under construction – not a live service

Skip to content

Frontlight Research

Institution

NYU Langone’s Laura and Isaac Perlmutter Cancer Center

New York, United StatesWebsite

Also known as: Laura and Isaac Perlmutter Cancer Center · Laura and Isaac Perlmutter Cancer Center at NYU Langone Health · NYU Langone Cancer Center · NYU Perlmutter Cancer Center · Perlmutter Cancer Center · Perlmutter Cancer Center at NYU Langone Health

88running trials
36closed trials
4,801publications (OpenAlex)

Running trials

Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795· Phase 2· Verastem, Inc.· Source
Recruiting
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
NCT07660094· Phase 3· Candel Therapeutics, Inc.· Source
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960· Phase 1/2· Blueprint Medicines Corporation· Source
Not yet recruiting
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NCT07567014· Phase 2· NYU Langone Health· Source
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338· Phase 1/2· Revolution Medicines, Inc.· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
NCT07285694· Phase 1/2· Arsenal Biosciences, Inc.· Source
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537· Phase 1· Revolution Medicines, Inc.· Source
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Taiho Oncology, Inc.· Source
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· Phase 2· Incyte Corporation· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926· Phase 1/2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
NCT06905197· Phase 1· Dizal Pharmaceuticals· Source
Recruiting
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177· Phase 2· Endevica Bio· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Genmab· Source
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126· Phase 3· Immatics US, Inc.· Source
Recruiting
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076· Phase 1/2· BlossomHill Therapeutics· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307· Phase 1· Stemline Therapeutics, Inc.· Source
Recruiting
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524· Phase 2· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· Phase 3· Kite, A Gilead Company· Source
Active, not recruiting
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
NCT06462183· Phase 1· Rgenta Therapeutics Inc· Source
Recruiting
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
NCT06549465· Phase 2· Convergent Therapeutics· Source
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044· Phase 1· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402· Phase 1· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519· Phase 1/2· 858 Therapeutics, Inc.· Source
Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411· Phase 1· Nested Therapeutics, Inc· Source
Active, not recruiting
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021· Phase 1/2· Affini-T Therapeutics, Inc.· Source
Active, not recruiting
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915· Phase 1/2· Arsenal Biosciences, Inc.· Source
Recruiting
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
NCT05952934· Phase 2· University of Arkansas· Source
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898· Phase 1· SystImmune Inc.· Source
Active, not recruiting
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110· Phase 2· Eikon Therapeutics· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511· Phase 1/2· Regeneron Pharmaceuticals· Source
Active, not recruiting
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443· Phase 1/2· OncoC4, Inc.· Source
Active, not recruiting
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760· Phase 3· Merck Sharp & Dohme LLC· Source

Showing 50 of 88.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer15 recruiting
Colorectal cancer7 recruiting
Multiple myeloma6 recruiting
Ovarian cancer5 recruiting
Prostate cancer5 recruiting
Head and neck cancer4 recruiting
Melanoma4 recruiting
Metastatic breast cancer4 recruiting
Pancreatic cancer4 recruiting
Bladder cancer3 recruiting
Endometrial cancer3 recruiting
Childhood cancers2 recruiting
Gastric and oesophageal cancer2 recruiting
Kidney cancer2 recruiting
Sarcoma2 recruiting
Triple-negative breast cancer2 recruiting
Acute myeloid leukaemia1 recruiting
Cervical cancer1 recruiting
Chronic myeloid leukaemia1 recruiting
Liver and biliary tract cancer1 recruiting
Myelodysplastic syndromes1 recruiting

Closed trials

Recruiting
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06457503· Phase 4· Coherus Oncology, Inc.· Source
Terminated
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958· Phase 1· AbbVie· Source
Terminated
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
NCT05999968· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329· Phase 2· Teligene US· Source
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058· Phase 2· Boehringer Ingelheim· Source
Completed
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
NCT05665530· Phase 1· Prelude Therapeutics Incorporated· Source
Terminated
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
NCT05846646· Phase 2· ImmuneSensor Therapeutics Inc.· Source
Terminated
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
NCT05828589· Phase 1· BeOne Medicines· Source
Completed
A Study of CDX-585 in Patients With Advanced Malignancies
NCT05788484· Phase 1· Celldex Therapeutics· Source
Completed
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
NCT05639751· Phase 1· Prelude Therapeutics Incorporated· Source
Completed
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
NCT05538572· Phase 1· Prelude Therapeutics Incorporated· Source
Completed
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377· Phase 2· Boehringer Ingelheim· Source
Terminated
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
NCT05242822· Phase 1· Kinnate Biopharma· Source
Terminated
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05252390· Phase 1· Nuvation Bio Inc.· Source
Terminated
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
NCT05241873· Phase 1· Blueprint Medicines Corporation· Source
Terminated
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT04958785· Phase 2· Gilead Sciences· Source
Completed
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
NCT04879849· Phase 1· Takeda· Source
Terminated
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NCT04862780· Phase 1· Blueprint Medicines Corporation· Source
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Completed
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771· Phase 2· Incyte Corporation· Source
Completed
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
NCT04165083· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250· Phase 1/2· Taiho Pharmaceutical Co., Ltd.· Source
Completed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source
Terminated
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Completed
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
NCT04165096· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT04165070· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165798· Merck Sharp & Dohme LLC· Source
Completed
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
NCT03783078· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
NCT03797326· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· Phase 3· pharmaand GmbH· Source
Completed
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NCT02621151· Phase 2· NYU Langone Health· Source

Registry name variants (51)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York 10016
30 trials
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York 10016
10 trials
Laura and Isaac Perlmutter Cancer Center
New York, New York 10016
9 trials
NYU Langone Health Perlmutter Cancer Center
New York, New York 10016
7 trials
NYU Langone Health Laura and Isaac Perlmutter Cancer Center
New York, New York 10016
5 trials
Perlmutter Cancer Center at NYU Langone Health
New York, New York 10016
5 trials
Perlmutter Cancer Center, NYU Langone Health
New York, New York 10016
5 trials
Laura and Isaac Perlmutter Cancer Center/ NYU Langone Health
New York, New York 10016
3 trials
- NCT05783622Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
- NCT05538572A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- NCT01042379I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  Contact: Yannis Karamitas
Laura & Isaac Perlmutter Cancer Center - NYU ACC
New York, New York 10016
3 trials
- NCT06012435A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- NCT05580562ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
  Contact: Clinical Trial Disclosure & Transparency
- NCT04553133PF-07104091 as a Single Agent and in Combination Therapy
NYU Perlmutter Cancer Center
New York, New York 10016
3 trials
- NCT02975934A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
- NCT02621151Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
- NCT02752685Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Perlmutter Cancer Center
New York, New York 10016
3 trials
- NCT02546102Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
- NCT05828511A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT01844986Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Perlmutter Cancer Center - 34th Street
New York, New York 10016
3 trials
- NCT07128199A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
  Contact: Taiho Oncology, Inc.
- NCT06010329A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
  Contact: Xiaoyang Xia
- NCT04256317A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
  Contact: Taiho Oncology, Inc.
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0034)
New York, New York 10016
2 trials
- NCT04165083KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
- NCT04165798KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
  Contact: Toll Free Number
Laura and Isaac Perlmutter Cancer Center (Site 0034)
New York, New York 10016
2 trials
- NCT04165096KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
- NCT04165070KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
  Contact: Toll Free Number
Laura & Isaac Perlmutter Cancer Center
New York, New York 10016
2 trials
- NCT06549465Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
  Contact: David Wise, MD (principal investigator)
- NCT05548296A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
  Contact: Karen Estok
Laura & Isaac Perlmutter Cancer Center - NYU Langone Health
New York, New York 10016
2 trials
- NCT05951179Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
  Contact: Chief Scientific Operations Officer
- NCT05252390NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Perlmutter Cancer Center - Sunset Park
Brooklyn, New York 11220
2 trials
- NCT06760637Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- NCT06638307A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
  Contact: Nancy Chan (principal investigator)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0002)
New York, New York 10016
1 trial
- NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0006)
New York, New York 10016
1 trial
- NCT03783078Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0019)
New York, New York 10016
1 trial
- NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0023)
New York, New York 10016
1 trial
- NCT03797326Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0038)
New York, New York 10016
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0111)
New York, New York 10016
1 trial
- NCT06833073A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
  Contact: Study Coordinator
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 1074)
New York, New York 10016
1 trial
- NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 2014)
New York, New York 10016
1 trial
- NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 3042)
New York, New York 10016
1 trial
- NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Laura and Isaac Perlmutter Cancer Center (Site 0003)
New York, New York 10016
1 trial
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
Laura and Isaac Perlmutter Cancer Center (Site 0010)
New York, New York 10016
1 trial
- NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Laura and Isaac Perlmutter Cancer Center (Site 0076)
New York, New York 10016
1 trial
- NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
  Contact: Study Coordinator
Laura and Isaac Perlmutter Cancer Center (Site 0137)
New York, New York 10016
1 trial
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Laura and Isaac Perlmutter Cancer Center (Site 1016)
New York, New York 10016
1 trial
- NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Laura and Isaac Perlmutter Cancer Center (Site 1582)
New York, New York 10016
1 trial
- NCT04428151Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Laura and Isaac Perlmutter Cancer Center (Site 3016)
New York, New York 10016
1 trial
- NCT04626518Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Laura and Isaac Perlmutter Cancer Center (Site 4106)
New York, New York 10016
1 trial
- NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Laura and Isaac Perlmutter Cancer Center (Site 5016)
New York, New York 10016
1 trial
- NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
  Contact: Study Coordinator
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC
New York, New York 10016
1 trial
- NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
  Contact: Revolution Medicines Study Director
Laura & Isaac Perlmutter Cancer Ctr
New York, New York 10016
1 trial
- NCT04463771Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NYU Investigational Pharmacy, Laura & Isaac Perlmutter Cancer Center
New York, New York 10016
1 trial
- NCT04958785Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NYU Langone Cancer Center
New York, New York 10016
1 trial
- NCT05242822A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
NYU Langone Health, Laura & Isaac Perlmutter Cancer Center
New York, New York 10016
1 trial
- NCT05682443ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NYU Langone Health Perlmutter Cancer Center - Manhattan
Manhattan, New York 10016
1 trial
- NCT07567014Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
  Contact: Oscar B. Lahoud, MD
NYU Langone Health-Perlmutter Cancer Center (Site 1917)
New York, New York 10016
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NYU Langone Health Perlmutter Cancer Center - Sunset Park
Brooklyn, New York 11220
1 trial
- NCT07567014Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
  Contact: Oscar B. Lahoud, MD
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 226141
New York, New York 10016-4744
1 trial
- NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 252708
New York, New York 10016-4744
1 trial
- NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943
New York, New York 10016
1 trial
- NCT06158958A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Perlmutter Cancer Center - 38th Street
New York, New York 10016
1 trial
- NCT06619236Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Perlmutter Cancer Center at NYU Langone Health
Mineola, New York 11501
1 trial
- NCT05952934Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
  Contact: Zujun Li, MD
Perlmutter Cancer Center at NYU Langone Health (contact for more locations)
New York, New York 10016
1 trial
- NCT07659795A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
  Contact: Rafael Winograd, MD, PhD
Perlmutter Cancer Center - Manhattan - 34th Street
New York, New York 10016
1 trial
- NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Perlmutter Cancer Centre
New York, New York 10016
1 trial
- NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Conditions

Diseases this institution publishes on or runs trials for.

Pancreatic cancer28 works · 13 trials
Endometrial cancer18 works · 10 trials
Hodgkin lymphoma14 works · 1 trial
Mesothelioma5 works · 1 trial

Institution data: ROR 00sa8g751 (CC0-1.0)Updated 10 Nov 2026

Report an error